Related Experiment Video
Updated: Jul 19, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
[Prediction of clinical efficacy of levitra (vardenafil) in patients with arteriogenic erectile dysfunction]
Abstract:
Oral inhibitors of phosphodiesterase of type 5 (PDE-5) are drugs of choice in therapy of erectile dysfunction (ED). However, 20-30% patients do not respond to them. We studied potentialities of ultrasonic investigation (UI) of postcompression increase in cavernous arteries diameter (PICAD) after intake of vardenafil (levitra, Bayer&GlaxoSmithKline) which is a PDE-5 inhibitor in prediction of clinical efficacy of this medicine. A total of 75 males with ED participated in the study. Significant correlations were found between PICAD after vardenafil administration and clinical efficacy of the drug in patients with arteriogenic ED. The highest response to the drug was observed at PICAD value > or = 50%. High sensitivity and specificity of the PICAD threshold value obtained indicate high potentialities of the method in decision making on treatment policy in patients with organic ED.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Dose-Response Relationship: Potency and Efficacy
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...